SCHEMBL860137

SCHEMBL860137

Nc1ccn2ncc(C=C3NC(=O)NC3=O)c2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CGAS Q8N884 1/20 0.38
CSNK2B P67870 2/20 0.38
KDM4E B2RXH2 5/20 0.37
MAPT P10636 3/20 0.37
GAA P10253 3/20 0.37
PIM1 P11309 1/20 0.37
HPGD P15428 4/20 0.37
ALDH1A1 P00352 3/20 0.37
PKM P14618 1/20 0.37
LMNA P02545 2/20 0.36
RAB9A P51151 2/20 0.36
GSK3B P49841 3/20 0.35
POLB P06746 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12978970 1.00 CGAS (0.38) CGASCSNK2BKDM4EMAPTGAA
SCHEMBL860136 1.00 CGAS (0.38) CGASCSNK2BKDM4EMAPTGAA
SCHEMBL12979110 0.79 SMPD3 (0.51) PIM1
SCHEMBL860773 0.79 MEN1 (0.38) CGASCSNK2BKDM4EMAPTGAA
SCHEMBL860772 0.79 MEN1 (0.38) CGASCSNK2BKDM4EMAPTGAA
SCHEMBL12979184 0.79 MEN1 (0.38) CGASCSNK2BKDM4EMAPTGAA
SCHEMBL861194 0.79 SMPD3 (0.51) PIM1
SCHEMBL861193 0.79 SMPD3 (0.51) PIM1
SCHEMBL3483134 0.77 PIM1 (0.40) CSNK2BKDM4EMAPTPIM1HPGD
SCHEMBL3483235 0.77 CSNK2B (0.43) CGASCSNK2BKDM4EMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 CGAS 726/4885CSNK2B 71/4885KDM4E 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.